This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Treatment approach
Overview of recommended treatment considerations across the multiple myeloma care continuum
- Clinical trials should be considered across all lines of therapy1,2
- Supportive care has an important place throughout the myeloma treatment journey3
| NDMM1,3 | 1-3 prior LOT2,3 | ≥4 prior LOT2,3 | |
|---|---|---|---|
| TE |
Induction + ASCT + maintenance |
FDA-approved regimens ASCT* CAR-T* |
FDA-approved regimens CAR-T* Palliative care |
| TENI TIE |
Continuous therapy |
*If eligible.
ASCT, autologous stem cell transplant; CAR-T, chimeric antigen receptor T cell; LOT, line of therapy; MM, multiple myeloma; NDMM, newly diagnosed multiple myeloma; TE, transplant eligible; TENI, transplant eligible, not intended; TIE, transplant ineligible.
1. mSMART Mayo stratification for myeloma and risk-adapted therapy newly diagnosed myeloma. Version 22. Accessed July 30, 2026. https://www.msmart.org/mm-treatment-guidelines. 2. mSMART Mayo stratification for myeloma and risk-adapted therapy relapsed myeloma. Version 8. Accessed July 30, 2026. https://www.msmart.org/mm-treatment-guidelines. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma v5.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed July 30, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.